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Prescription Drug Prices Will Drive Health Insurance
Premium Increases in 2017
Jeff Rubleski, MBA, Director, Sales Strategy, Blue Cross Blue Shield of Michigan
Adjunct Faculty Member, Seidman School of Business
The top driver of rising health
insurance premiums for 2017 is
the cost of prescription drugs.
Medical inflation for health
insurance premiums is
measured by a term referred
to as “trend.” In 2017, the
prescription drug trend is
projected to be 11.6 percent, up
from 11.3 percent in 20161. The
annual prescription drug trend
is alarming, considering that it
is almost a 7x multiple of general inflation in our economy,
represented by the Consumer
Price Index (CPI).2 Based on a host of factors, including
individuals being treated at an increased rate for chronic
conditions and diseases, aggressive pharmaceutical price
increase policies for existing drugs and the introduction
of new and very expensive drug therapies, it appears that
annual drug price trend increases will continue at a pace that
widely exceeds the CPI for years to come.
The single largest factor behind the year-over-year increase
in prescription drug trend involves what are labeled as
specialty drugs, which treat complex conditions such as
cancer, hepatitis C, arthritis, multiple sclerosis, and a multitude
of other chronic and debilitating medical conditions and
diseases. Advances in complex genetic research over the past
decade have served as the catalyst for the development of
these drugs. Pharmaceutical companies collectively spend
billions of dollars to develop specialty drugs that have a high
risk of failure, as most specialty drugs do not pass stringent
Food and Drug Administration (FDA) testing that is required
before prescription drugs are approved to go to market.
However, the relatively few specialty drugs that do pass FDA
testing once introduced to consumers can produce “lottery
ticket-like” revenues and profits for pharmaceutical
companies. To put into context the cost impact of specialty
drugs, consider that they account for less than 1 percent of
all prescribed medications, yet they account for about
35 percent of total prescription drug cost trends for 2017!3
For pharmaceutical companies, the high risk and correspondingly
high return nature of specialty drug development make them a
top priority for market introduction. It appears that this trend will
continue to accelerate in future years with scores of promising
new specialty drugs in the pipelines of many pharmaceutical

companies. All of this translates into continued development of
new specialty drugs that can treat and cure debilitating and even
terminal conditions, yet at a cost that is increasingly becoming
a financial burden for both consumers who use and pay more
to acquire the medications and businesses that pay most of the
cost of prescription drugs through company-sponsored health
insurance programs. In a 2016 health care tracking poll, The Kaiser
Family Foundation discovered that one in four people in the
United States have trouble paying for their medication.4 Expect
affordability issues to increase in future years as businesses and
consumers are forced to absorb the increasing cost of the
ever-growing list of specialty drugs.

Specialty Drugs—the “Silver Lining”
for Consumers

Specialty drugs produce powerful life-enhancing and
sometimes life-saving results for consumers who need them.
They can deliver rates of cure from disease and long-term
relief from chronic health conditions that just a decade ago
would have been impossible to treat with traditional drug
therapies. For example, hepatitis C is a terrible disease that
afflicts an estimated 3.5 million Americans. In 2014, the Centers
for Disease Control (CDC) documented 19,659 deaths from
hepatitis C, making it the leading cause of death of Americans
from infectious disease.5 In 2013 and 2014 the specialty drugs
Sovaldi and Harvoni received FDA approval as a cure for
hepatitis C. These drugs provide a cure of hepatitis C for over
90 percent of the patients who receive treatment. But the cost
of both drugs is staggering and out of financial reach for those
who do not have some form of insurance coverage or external
subsidy. The average cost for Harvoni is $94,500 for a 12 week
treatment program, resulting in a cost of over $1,100 per pill!
(Note that a 12 week treatment of Sovaldi is about $84,000 or
around $1,000 per pill.)6 These drugs are often combined with
other drug therapies when treating hepatitis C, resulting in a
total price tag that often exceeds $100,000 to treat and cure
hepatitis C.
Naturally health insurance premiums are directly impacted
by rising prescription drug costs. Figure 1 shows the
breakdown of key components that factor into the pricing
of health insurance premiums.7 Note that prescription drugs
represent the largest component of the total premium
expenditure for health insurance, accounting for 29% of
total health insurance premiums.
Just a few years ago, prescription drug spending accounted
for less than 20% of the total health insurance premium

1 Segal 2017 Health Plan Cost Trend Survey, September 27, 2016, www.segalco.com.
2 Bureau of Labor Statistics, September 2016 CPI Detailed Report, www.bls.gov.
3 Segal 2017 Health Plan Cost Trend Survey, September 27, 2016, www.segalco.com.
4 Kaiser Family Foundation Health Tracking Poll, September 2016, www.kff.org.
5 Centers for Disease Control, Clinical Infectious Diseases online publication, May 4, 2016.
6 Hepatitis C Society, 2016.
7 Blue Cross Blue Shield of Michigan Book of Business Analysis 2015.
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expenditure, so rapidly growing prescription drug spending is
a concern for both employers who continue to pay for a
majority of health insurance premiums and for employees, who
likely are now paying much more in out-of-pocket expenses to
obtain necessary pharmacy benefits than they did just a couple
of years ago.

Figure 1: Medical Service Costs
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Four Actionable Strategies for Controlling
Rising Prescription Drug Costs

With drug costs continuing to rise, there are a number of
strategies businesses can take to control cost and to
encourage employees and their covered family members to
utilize the lowest priced prescription drug therapy to treat a
diagnosed condition. Here are four strategies to consider when
managing the rising cost of prescription drugs:
1. Consider adopting or modifying any existing multi-tier
prescription drug benefit. Insurance carriers and pharmacy
benefit managers now offer a variety of prescription drug
tiers in an effort to direct covered members to the lowest
cost drug therapy. The most common multi-tier formats offer
4 to 6 tiers, with each tier representing a higher out-of-pocket
drug cost for the member. Specialty drugs are represented in
the last tier and carry the highest out-of-pocket cost. Be sure
to understand the likely wide spectrum of multi-tier options
available, including deductibles linked to prescription drug
spending, fixed copayment, and coinsurance payments per
drug tier. Making thoughtful adjustments to your pharmacy
benefit can save significant premium dollars.
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2. E
 ducate employees on the cost of prescription drugs
through targeted communications. With more employers
introducing multi-tier prescription drug benefits that shift
cost to members for higher tier drug use, it is important for
your employees and their covered family members to
understand why the sometimes confusing multi-tier approach
is necessary and how they can lower their out-of-pocket
costs by asking their health care provider to prescribe
generics whenever possible. Your insurance company or
pharmacy benefit manager should have a number of turn-key
communications available to help you to communicate with
employees and covered family members.
3. Work with a good health benefits agent or consultant to
help you to navigate your prescription drug options and to
recommend options that make the most sense for your
organization. A good agent should present a number of
viable prescription drug options for consideration and should
also provide guidance on how to communicate coverage
changes to employees and family members. Also seek the
input of your current insurance carrier or current pharmacy
benefit manager for their insight on what your organization
can do to control rising costs while still providing a solid
prescription drug benefit for your employees and their
covered family members.
4. If your group is self insured or is experience rated for medical
and prescription drug claims (typically if your group insures
more than 50 employees, your plan will be experience rated),
consider purchasing stop-loss coverage for prescription drug
costs that exceed a designated level at the employee
contract level (referred to as specific stop-loss coverage) and
for the total amount of group pharmacy expenses (referred
to as aggregate stop-loss coverage). For many companies,
this extra form of risk reduction stop-loss coverage will be a
good decision, as specialty pharmacy costs can exceed over
$100,000 for just one treatment regimen.
The cost of prescription drugs will continue to rise, and
understanding the factors that are driving these ongoing
increases will allow you to take proactive steps to keep
pharmaceutical premium increases in line with your health
insurance budget. The decisions you’ll need to make are by no
means easy, but will be necessary to keep health insurance a
viable option for your organization. Commit to understanding
the factors driving your organization’s pharmacy drug costs
and take advantage of plan design and strategies to keep the
rising cost of your pharmacy benefits in check.

